FDA to review Bausch + Lomb's intraocular lens

February 27, 2013 by Arezu Sarvestani

Bausch + Lomb lands a panel date with the FDA to review its Trulign Toric vision-correcting implant.

Bausch + Lomb logo

Eye care giant Bausch + Lomb won a date with the FDA for review of its Trulign Toric intraocular lens for improving vision in patient who have undergone cataract surgery.

On April 8, 2012, the FDA's Ophthalmic Devices Panel will review clinical data and cast a vote on the Trulign Toric implant in treatment of patients with vision impairment as a result of aphakia and postoperative refractive astigmatism.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp